RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)

The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amitech Therapeutic Solutions, Inc.

Basilea Pharmaceutica Ltd

CBT Pharmaceuticals Inc

Chugai Pharmaceutical Co Ltd

Hanmi Pharmaceuticals Co Ltd

Millennium Pharmaceuticals Inc

Novartis AG

Redx Pharma Plc

Sirnaomics Inc

VG Life Sciences Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) Overview 7

Therapeutics Development 8

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Products under Development by Stage of Development 8

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Products under Development by Therapy Area 9

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Products under Development by Indication 10

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Products under Development by Companies 13

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Products under Development by Universities/Institutes 15

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 19

Assessment by Molecule Type 21

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 23

Amitech Therapeutic Solutions, Inc. 23

Basilea Pharmaceutica Ltd 24

CBT Pharmaceuticals Inc 25

Chugai Pharmaceutical Co Ltd 26

Hanmi Pharmaceuticals Co Ltd 27

Millennium Pharmaceuticals Inc 28

Novartis AG 29

Redx Pharma Plc 30

Sirnaomics Inc 31

VG Life Sciences Inc 32

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Drug Profiles 33

BAL-3833 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

CBT-102 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

DCBCI-0902 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

FYA-1001 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

HM-95573 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

hydroxychloroquine + sorafenib tosylate - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

LXH-254 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

RG-7304 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecules to Inhibit Pan-RAF Kinase for Oncology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Inhibit Pan-Raf Kinases for Colorectal Cancer - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Inhibit Raf Kinases for Oncology - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

STP-503 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

TAK-580 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

TEW-0201 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Dormant Projects 51

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Discontinued Products 52

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC

2.7.11.1) - Featured News & Press Releases 53

Jun 17, 2016: Hanmi presented the clinical trial results of targeted anti-ancer drug HM95573 at ASCO 53

Jun 09, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at ASCO meeting 53

Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL3833 at AACR meeting 54

Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent 54

Nov 10, 2014: Hanmi To Initiate A Phase 1 Clinical Trial Of HM95573, The Next Generation Targeted Therapy For Melanoma Treatment 55

Sep 04, 2014: VG Life Sciences Progress Update Phase I Cancer Study 55

Mar 14, 2014: VG Life Sciences's Reports on Clinical Outcomes in Phase I Cancer Study 56

Dec 13, 2013: VG Life Sciences Update on Phase I Cancer Study 57

Jul 25, 2013: VG Life Sciences Reports on Scientific Advancements: Completion of Third Cohort of Phase I Clinical Trial; Grant from the American Heart Association; 58

Apr 04, 2013: VG Life Sciences Reports Positive Safety Results Of Hydroxychloroquine And Sorafenib Combination Therapy In Second Cohort Of Phase I Solid Tumor Study 59

Jan 31, 2013: VG Life Sciences Reports Positive Results From Phase I Ovarian Cancer Trial Using Sorafenib Combined With Hydroxychloroquine 59

Jan 14, 2013: VG Life Sciences Receives IRB Approval To Expand Phase I Cancer Trial Of Hydroxychloroquine In Combination With Sorafenib 60

Jul 19, 2012: Viral Genetics Begins Phase I Clinical Trial For Ovarian Cancer 60

Sep 26, 2011: Sunesis Initiates Phase I Study Of MLN2480 In Advanced Solid Tumors 62

Jul 13, 2009: Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec 62

Appendix 63

Methodology 63

Coverage 63

Secondary Research 63

Primary Research 63

Expert Panel Validation 63

Contact Us 63

Disclaimer 64

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Amitech Therapeutic Solutions, Inc., H2 2016 23

Pipeline by Basilea Pharmaceutica Ltd, H2 2016 24

Pipeline by CBT Pharmaceuticals Inc, H2 2016 25

Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 26

Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 27

Pipeline by Millennium Pharmaceuticals Inc, H2 2016 28

Pipeline by Novartis AG, H2 2016 29

Pipeline by Redx Pharma Plc, H2 2016 30

Pipeline by Sirnaomics Inc, H2 2016 31

Pipeline by VG Life Sciences Inc, H2 2016 32

Dormant Projects, H2 2016 51

Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 18

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared